Recombinant Factor VIIa

Summary

November 2018
As of October 2018, given the absence of strong evidence of benefit and with evidence demonstrating a greater risk of harm, the NAC continues to recommend that rFVIIa not be used for off label indications.

April 2012
On behalf of NAC, Dr. Yulia Lin et al. has revised the FVIIa transfusion policy framework.  It is available online as an open access publication.

Date of Original Release

Table of Contents